Aurobindo Pharma Subsidiary Apitoria Pharma Receives US FDA VAI Classification for Andhra Pradesh Facility


Aurobindo Pharma's Apitoria unit gets 'voluntary action indicated' classification from USFDA

Aurobindo Pharma | The drugmaker’s long-term chart shows a retest of a breakout zone around ₹1,000 – ₹1,100. The strong bullish candle shows renewed buying interest and the recent price action shows the stock extending its advance. Axis Securities recommends buying in the range of ₹1,550 – ₹1,470, with supports at ₹1,380 – ₹1,300 for upside towards ₹1,880 – ₹2,100 levels, which is a 25% to 39% return potential over the new Samvat.

Clearing the inspection hurdle allows the drugmaker to avoid strict regulatory action, though corrective steps remain necessary for the active pharmaceutical ingredient plant. Find out how this resolution impacts upcoming export pipelines for the facility.

Aurobindo Pharma on Saturday, November 21, said its wholly-owned subsidiary, Apitoria Pharma, has received a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (FDA) for its API manufacturing facility in Andhra Pradesh.

The US FDA inspected the facility at Unit-VI in E-Bonangi village, Anakapalli district, between August 24 and August 28, 2026. The inspection ended with three observations.

The company has now received the Establishment Inspection Report (EIR), which classifies the facility as VAI. The US FDA has also closed the inspection, Aurobindo Pharma said in an exchange filing.

VAI means the FDA has identified issues that the company needs to address voluntarily but does not intend to take regulatory action based on the inspection findings at this stage. It is a more favourable outcome than an Official Action Indicated (OAI) classification, which can lead to regulatory action.

However, VAI does not mean the facility has received a clean chit, as the observations still need to be addressed.

Aurobindo Pharma shares closed marginally lower at ₹1,799 apiece on the NSE on November 20. 

Home/Market News/

Aurobindo Pharma’s Apitoria unit gets ‘voluntary action indicated’ classification from USFDA



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *